Thousands of heart surgery kits recalled | TAVR for AR linked to 'encouraging' data | Carotid IVL | Progress for new HCM drug

Specific lots of several procedure kits have been recalled after the FDA identified quality issues during a recent inspection.

All patients presented with severe aortic regurgitation. The study's findings were presented at New York Valves 2026 and published in JSCAI.

Carotid artery disease causes up to 30% of all strokes, but severely calcified lesions can make treatment quite complex. The hope is that IVL can be as successful in this area as it has been in the treatment of coronary and peripheral artery disease. 

No drugs are currently approved by the FDA for the treatment of symptomatic, nonobstructive HCM. Could oral therapy ninerafaxstat be the first?

“We have colonoscopies, we have mammograms, but we have not had equivalents for most forms of heart disease,”  Pierre Elias, MD, Pathway Labs founder and CEO, explained.

Treating certain high-risk PCI patients with nicorandil before and after treatment can significantly reduce their risk of contrast-related injuries.

One of the platform's biggest benefits is the rich clinical information it provides to all members of the care team.

Cathie Biga, MSN, a former ACC president, says salary is just one thing a cardiologist should ask about before signing any contract.

The FDA is once again warning the public about a safety issue with certain Impella heart pumps. 

The software-only platform helps clinicians keep track of patients when they are at their most vulnerable.

Legislative changes, demographic shifts and growing demand will combine to drive national health spending to almost $9 trillion by 2034.

The lawsuit dates back to 2019 but has been stuck in the court process for years. In the end, the health plan will pay Pomona Valley Hospital for emergency care delivered to patients at an out-of-network rate—though the facility didn’t get all of what it was seeking.